Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of MK-0616 in adults with hypercholesterolemia
CTR20242333Phase 3Active
- Sponsor
- 不适用/ 默沙东研发（中国）有限公司
- Start
- Nov 2024
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enlicitide in hypercholesterolemia, sponsored by 不适用/ 默沙东研发（中国）有限公司. Started Nov 2024; status: active.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on CTR20242333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242333.